Physician profile
Janet E Lubas
NPI 1326011149
$1,699.89
in general payments reported to CMS, 2019-2025
24 companies · $240 in 2025
The $240 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $625 · 2020: $332 · 2021: $53.94 · 2022: $14.78 · 2023: $18.16 · 2024: $416 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $674.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $360.13 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $248.82 | 2019-2024 | Xarelto |
| Pfizer INC. | $209.98 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $188.81 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $99.94 | 2021-2025 | Gvoke Hypopen |
| Novo Nordisk INC | $90.67 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $71.10 | 2019 | |
| Abbvie INC. | $60.18 | 2019-2024 | |
| Edwards Lifesciences Corporation | $46.93 | 2019-2025 | |
| Mylan Specialty L.P. | $42.34 | 2019 | |
| Astellas Pharma US INC | $31.17 | 2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $29.59 | 2020 | |
| Biosense Webster, INC. | $26.47 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2019 | |
| Heartflow, INC. | $22.75 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $21.81 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $21.66 | 2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $18.16 | 2023 | |
| Dynavax Technologies Corporation | $17.07 | 2025 | Heplisav-B |
| Vifor Pharma, INC. | $14.87 | 2020 | |
| Boston Scientific Corporation | $13.63 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2020 | |
| Amgen INC. | $12.53 | 2020 | |
| Corcept Therapeutics | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Lubas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.